Factor Xa Inhibitor-Related Intracranial Hemorrhage
Top Cited Papers
- 26 May 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 141 (21), 1681-1689
- https://doi.org/10.1161/circulationaha.120.045769
Abstract
Background: Since the approval of the oral factor Xa (FXa) inhibitors, there have been concerns regarding the ability to neutralize their anticoagulant effects after intracranial hemorrhage (ICH). Multiple guidelines suggest using prothrombin complex concentrates (PCC) in these patients based upon research that includes a limited number of patients with ICH. Given this, we aimed to evaluate the safety and efficacy of PCC for FXa inhibitor-related ICH in a large, multicenter cohort of patients. Methods: This was a multicenter, retrospective, observational cohort study of patients with apixaban or rivaroxaban-related ICH who received PCC between January 1, 2015 and March 1, 2019. The study had two primary analysis groups: safety and hemostatic efficacy. The safety analysis evaluated all patients meeting inclusion criteria for the occurrence of a thrombotic event, which were censored at hospital discharge or 30 days following PCC administration. Patients with intracerebral, subarachnoid, or subdural hemorrhages who had at least one follow-up image within 24 hours of PCC administration were assessed for hemostatic efficacy. The primary efficacy outcome was the percentage of patients with excellent or good hemostasis based upon the modified Sarode criteria. Secondary outcomes included an evaluation of in-hospital mortality, length of stay, infusion-related reactions and thrombotic event occurrence during multiple pre-defined periods. Results: A total of 663 patients were included and assessed for safety outcomes. Of these, 433 patients met criteria for hemostatic efficacy evaluation. We observed excellent or good hemostasis in 354 patients (81.8%; 95% confidence interval 77.9 - 85.2). Twenty-five (3.8%) patients had a total of 26 thrombotic events, of which 22 occurred in the first 14 days following PCC administration. One patient had documentation of an infusion-related reaction. For the full cohort of patients, in-hospital mortality was 19.0% and the median intensive care unit and hospital length of stay were 2.0 and 6.0 days, respectively. Conclusions: Administration of PCC after apixaban and rivaroxaban-related ICH provided a high rate of excellent or good hemostasis (81.8%) coupled with a 3.8% thrombosis rate. Randomized, controlled trials evaluating the clinical efficacy of PCC in patients with FXa inhibitor-related ICH are needed.Keywords
This publication has 26 references indexed in Scilit:
- Reversibility of Apixaban Anticoagulation with a Four‐Factor Prothrombin Complex Concentrate in Healthy VolunteersClinical and Translational Science, 2016
- Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2016
- Guideline for Reversal of Antithrombotics in Intracranial HemorrhageNeurocritical Care, 2015
- Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa InhibitorsWorld Neurosurgery, 2015
- Guidelines for the Management of Spontaneous Intracerebral HemorrhageStroke, 2015
- Management of bleeding and reversal strategies for oral anticoagulants: Clinical practice considerationsAmerican Journal of Health-System Pharmacy, 2013
- Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major BleedingCirculation, 2013
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patientsJournal of Thrombosis and Haemostasis, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2008
- Interval Estimation for a Binomial ProportionStatistical Science, 2001